{"prompt": "['Charit\u00e9 Universit\u00e4tsmedizin Berlin', 'Prof. Dr. med. Dominik Modest', 'FIRE-9 PORT', '28-Sep-2021', 'EudraCT no. 2020-006144-18', 'Protocol Version 3.0', 'Review / documentation of prior and concomitant medication', 'Administration of mFOLFOXIRI or mFOLFOX-6 or de-escalated treatment regimens, if', 'applicable.', 'Day 1 of Cycle 2-12 (assessments can be performed up to 2 days before application of drugs):', 'Assessment of Covid-19 should be conducted according to the actual pandemic', 'situation AND institutional policy that is applied to any patient that receives', 'FOLFOX/FOLFOXIRI for colorectal cancer outside the trial. This may require', 'assessment of vaccination status, physical examination, anamnesis and Covid-19 tests', '(e.g. antigen test and/or PCR testing). SARS-CoV-2-positive patients should not', 'participate in the trial or chemotherapy application should be delayed as long as the', 'patient is positive for SARS-CoV-2.', 'Review / documentation of prior and concomitant medication', 'Administration of mFOLFOXIRI or mFOLFOX-6 or de-escalated treatment regimens, if', 'applicable.', 'During Cycle 2-12:', 'WOCBP only: Pregnancy Test - urine or serum \u00df-HCG - to be performed at every', 'second cycle (at least monthly) during treatment and until the end of relevant systemic', 'exposure to the study drug (i.e. ~30 days after the last dose), in accordance with the', 'CTFG guidance on contraception.', \"Quick's time [PT/INR] (only in case of concomitant use of 5-FU and oral anticoagulants)\", 'Directed Physical Examination.', 'Weight and Vital Signs (temperature, pulse and blood pressure).', '12-Lead Electrocardiogram at Cycle 7', 'CBC with differential.*', 'Comprehensive serum chemistry panel.', '*besides the frequency of the laboratory assessments, which should be scheduled according to study site standards', 'or as clinically indicated, also the type of lab parameters to be tested should follow study site standards.', 'End of trial intervention:', 'Full Physical Examination', 'Weight and Vital Signs (temperature, pulse and blood pressure)', '12-Lead Electrocardiogram', \"Quick's time [PT/INR] (only in case of concomitant use of 5-FU and oral anticoagulants)\", 'CBC with differential:', 'Confidential', 'Page 50 of 79']['Charit\u00e9 Universit\u00e4tsmedizin Berlin', 'Prof. Dr. med. Dominik Modest', 'FIRE-9 PORT', '28-Sep-2021', 'EudraCT no. 2020-006144-18', 'Protocol Version 3.0', 'White Blood Cell (WBC) count with differential and Absolute Neutrophil Count (ANC);', 'Absolute Lymphocyte Count (ALC); Red Blood Cells (RBCs); Platelet count;', 'Haemoglobin; Haematocrit.', 'Comprehensive serum chemistry panel:', 'Alkaline phosphatase; Aspartate aminotransferase (AST); Potassium; Sodium; Total', 'Bilirubin; Direct Bilirubin (if total bilirubin is elevated above the upper limit of normal);', 'Creatinine.', '6.1.5.3 Structured Follow-up (Arm A and B)', 'To be performed as part of the structured follow-up.', 'Every 3 months during the first 24 months after randomization:', 'ECOG Performance Status', 'Review Adverse Events (at each visit during trial intervention for Arm A)', 'Further anticancer therapy status (to be documented if and when new anticancer', 'therapy (systemic and/or local) is initiated at the study site or if and when such', 'information becomes available to the investigator, in case a new therapy is started', 'somewhere else). All available information should be collected.', 'EQ5D5L Questionnaire', 'Tumor Imaging', 'Carcinoembryonic antigen', 'Every 6 months for up to 60 months after randomization:', 'Survival status', 'EQ5D5L Questionnaire', 'Tumor Imaging', 'Carcinoembryonic antigen', '6.2 Assessment of Safety', 'The respective SmPCs of routine chemotherapy medications will be used as reference', \"documents and will be provided to the investigators in the investigator's site file.\", '6.2.1 Adverse Events and Laboratory Abnormalities Reporting', 'It is the responsibility of the investigators to document all adverse events, pregnancy and', 'overdose in the eCRF. Any serious adverse event (SAE) must be reported immediately,', 'without undue delay, but not later than 24 hours after obtaining knowledge to the CRO who', 'will forward the SAEs to the Sponsor/Sponsor Representative within one working day.', 'Confidential', 'Page 51 of 79']\n\n###\n\n", "completion": "END"}